RESI Boston Innovator’s Pitch Challenge Winners

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

At RESI Boston 2024, 56 innovative companies participated in the Innovator’s Pitch Challenge (IPC), providing a unique platform for early-stage life science and healthcare companies to present their technologies and connect with potential investors.

The IPC finalists delivered 4-minute pitches and a 9-minute interactive Q&A session with a panel of investor judges. In addition, each participating company showcased its technology at its personalized table space in the RESI Exhibition Hall, creating further opportunities for engagement.

The Innovator’s Pitch Challenge features a distinctive voting system where registered RESI attendees—including startup executives, early-stage investors, and industry experts – ‘invest’ in their favorite IPC companies using RESI cash provided at check-in. Attendees based their decisions on the companies’ presentations and pitch performances.

For those interested in participating in the next Innovator’s Pitch Challenge, applications are now open for RESI London 2024 and RESI JPM 2025. Early application is encouraged as spots are filled on a rolling basis.

Life Science Nation is proud to announce the top three winners of RESI Boston 2024’s Innovator’s Pitch Challenge:

1st Place: Amplified Sciences

RESI-Boston-1st-Place Max Braht, Business Development Manager, Life Science Nation | Diana Caldwell, MBA,CEO and Co-Founder, Amplified Sciences | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

2nd Place: EYWA Biotech

RESI-Boston-2nd-Place Greg Mannix, VP, International Business Development, Life Science Nation | Victoria Costa Paz, CEO and Co-Founder, EYWA Biotech | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

3rd Place: RadioClash

RESI-Boston-3rd-Place Momo Yamamoto, Investor Research Analyst, Life Science Nation | John Qiao, Founder and CEO, RadioClash | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

The 56 companies were assigned to 14 different sessions throughout the day, with 4 companies grouped together based on similar sector or technology. These companies were evaluated by a panel of judges, and the following companies were the highest scorers. This attests to the high quality of their pitch, ability to answer questions, and clearly deliver their value proposition.

Judges Picks:

IPC-Judge-Picks

Comments Leave a Comment
Categories Redefining Every Stage Investments (RESI)

Hot Mandates

Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease

The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need

The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases

A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA

The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health

A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]

Search